Efficacy and safety of the biosimilar ABP 215 compared with Bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study
Purpose: This phase III study compared clinical efficacy and safety of the biosimilar ABP 215 with bevacizumab reference product (RP) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). - Patients and Methods: Patients were randomized 1:1 to ABP 215 or bevacizumab 15 mg/kg ever...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 7, 2019
|
| In: |
Clinical cancer research
Year: 2019, Jahrgang: 25, Heft: 7, Pages: 2088-2095 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-18-2702 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1158/1078-0432.CCR-18-2702 Verlag: https://clincancerres.aacrjournals.org/content/25/7/2088 
|
| Verfasserangaben: | Nicholas Thatcher, Jerome H. Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodriguez, Valery Breder, Gyula Ostoros, and Vladimir Hanes |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1688903380 | ||
| 003 | DE-627 | ||
| 005 | 20230426164722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200130s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-18-2702 |2 doi | |
| 035 | |a (DE-627)1688903380 | ||
| 035 | |a (DE-599)KXP1688903380 | ||
| 035 | |a (OCoLC)1341299975 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Thatcher, Nicholas |e VerfasserIn |0 (DE-588)1144315514 |0 (DE-627)1004522843 |0 (DE-576)495342858 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of the biosimilar ABP 215 compared with Bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE) |b a randomized, double-blind, phase III study |c Nicholas Thatcher, Jerome H. Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodriguez, Valery Breder, Gyula Ostoros, and Vladimir Hanes |
| 264 | 1 | |c January 7, 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.01.2020 | ||
| 520 | |a Purpose: This phase III study compared clinical efficacy and safety of the biosimilar ABP 215 with bevacizumab reference product (RP) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). - Patients and Methods: Patients were randomized 1:1 to ABP 215 or bevacizumab 15 mg/kg every three weeks for 6 cycles. All patients received carboplatin and paclitaxel every three weeks for ≥4 and ≤6 cycles. The primary efficacy endpoint was risk ratio of objective response rate (ORR); clinical equivalence was confirmed if the 2-sided 90% confidence interval (CI) of the risk ratio was within the margin of 0.67 to 1.5. Secondary endpoints included risk difference of ORR, duration of response (DOR), progression-free survival (PFS), and overall survival (OS); pharmacokinetics, adverse events (AEs), and incidence of antidrug antibodies (ADAs) were monitored. - Results: A total of 820 patients were screened; 642 were randomized to ABP 215 (n = 328) and bevacizumab (n = 314). Overall, 128 (39.0%) and 131 (41.7%) patients in the ABP 215 and bevacizumab groups, respectively, had objective responses [ORR risk ratio: 0.93 (90% CI, 0.80-1.09)]. In the ABP 215 and bevacizumab group, 308 (95.1%) and 289 (93.5%) patients, respectively, had at least 1 AE; 13 (4.0%) and 11 (3.6%) experienced a fatal AE. Anti-VEGF toxicity was low and comparable between treatment groups. At week 19, median trough serum drug concentration was 132 μg/mL (ABP 215 group) and 129 μg/mL (bevacizumab group). No patient tested positive for neutralizing antibodies. - Conclusions: ABP 215 is similar to bevacizumab RP with respect to clinical efficacy, safety, immunogenicity, and pharmacokinetics. The totality of evidence supports clinical equivalence of ABP 215 and bevacizumab. | ||
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 25(2019), 7, Seite 2088-2095 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a Efficacy and safety of the biosimilar ABP 215 compared with Bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE) a randomized, double-blind, phase III study |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g number:7 |g pages:2088-2095 |g extent:8 |a Efficacy and safety of the biosimilar ABP 215 compared with Bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE) a randomized, double-blind, phase III study |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-18-2702 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://clincancerres.aacrjournals.org/content/25/7/2088 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200130 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 3 | ||
| 999 | |a KXP-PPN1688903380 |e 3583367952 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Nicholas Thatcher, Jerome H. Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodriguez, Valery Breder, Gyula Ostoros, and Vladimir Hanes"]},"language":["eng"],"person":[{"role":"aut","given":"Nicholas","display":"Thatcher, Nicholas","family":"Thatcher"},{"family":"Thomas","role":"aut","given":"Michael","display":"Thomas, Michael"}],"title":[{"subtitle":"a randomized, double-blind, phase III study","title":"Efficacy and safety of the biosimilar ABP 215 compared with Bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE)","title_sort":"Efficacy and safety of the biosimilar ABP 215 compared with Bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE)"}],"id":{"doi":["10.1158/1078-0432.CCR-18-2702"],"eki":["1688903380"]},"physDesc":[{"extent":"8 S."}],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"January 7, 2019"}],"note":["Gesehen am 30.01.2020"],"recId":"1688903380","relHost":[{"recId":"325489971","pubHistory":["1.1995 -"],"origin":[{"publisherPlace":"Philadelphia, Pa. [u.a.]","publisher":"AACR","dateIssuedDisp":"1995-","dateIssuedKey":"1995"}],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"id":{"zdb":["2036787-9"],"eki":["325489971"],"issn":["1557-3265"]},"name":{"displayForm":["American Association for Cancer Research"]},"language":["eng"],"corporate":[{"display":"American Association for Cancer Research","role":"isb"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Efficacy and safety of the biosimilar ABP 215 compared with Bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE) a randomized, double-blind, phase III studyClinical cancer research","title":[{"title":"Clinical cancer research","title_sort":"Clinical cancer research"}],"part":{"year":"2019","pages":"2088-2095","text":"25(2019), 7, Seite 2088-2095","volume":"25","extent":"8","issue":"7"},"type":{"media":"Online-Ressource","bibl":"periodical"}}]} | ||
| SRT | |a THATCHERNIEFFICACYAN7201 | ||